The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 15, 2025
Filed:
Jun. 17, 2022
Applicants:
Syz Cell Therapy Co., Guangdong, CN;
Hryz Biotech Co., Guangdong, CN;
Inventors:
Assignees:
HRYZ (SHANGHAI) BIOTECH CO., Shanghai, CN;
HRYZ (GUANGZHOU) BIOTECH CO., Guangzhou, CN;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2025.01); A61K 40/11 (2025.01); A61K 40/19 (2025.01); A61K 40/24 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); A61K 40/46 (2025.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01); C12N 5/078 (2010.01); C12N 5/0783 (2010.01); C12N 5/0784 (2010.01); C12N 5/22 (2006.01); C12P 21/02 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/7051 (2013.01); A61K 40/11 (2025.01); A61K 40/19 (2025.01); A61K 40/24 (2025.01); A61K 40/32 (2025.01); A61K 40/4201 (2025.01); A61K 40/4205 (2025.01); A61K 40/4208 (2025.01); A61K 40/4232 (2025.01); A61K 40/4239 (2025.01); A61K 40/424 (2025.01); A61K 40/4241 (2025.01); A61K 40/4243 (2025.01); A61K 40/4246 (2025.01); A61K 40/4266 (2025.01); A61K 40/4268 (2025.01); A61K 40/4269 (2025.01); A61K 40/46 (2025.01); A61P 35/00 (2018.01); C12N 5/0636 (2013.01); C12N 5/0639 (2013.01); C12P 21/02 (2013.01); A61K 38/00 (2013.01); C12N 2502/1114 (2013.01); C12N 2502/1121 (2013.01);
Abstract
Provided methods of obtaining a plurality of T cell receptors specifically recognizing a target tumor antigen peptide from an individual that has clinically benefitted from an immunotherapy, such as Multiple Antigen Specific Cell Therapy. Also provided tumor-specific TCRs, engineered immune cells expressing the TCRs and methods of treating a disease using the engineered immune cells.